Lexaria Bioscience Corp. announced it will effect a 1-for-15 reverse stock split effective August 3, 2026, to regain compliance with Nasdaq's minimum $1.00 bid price requirement. The reverse split will consolidate the company's current 24,787,446 issued common shares into approximately 1,652,518 shares, with fractional shares rounded up, and will also proportionally adjust authorized shares from 220 million to about 14.67 million as well as outstanding convertible securities and their exercise prices. CEO Richard Christopher stated the move is critical for maintaining the Nasdaq listing and supporting business development and investor appeal amid recent equity market weakness. The company noted it examined 24 other reverse splits by Nasdaq-listed biotech firms in the first half of 2026, which averaged a 1-for-18 ratio. Following the split, shares will continue trading under the symbol LEXX with a new CUSIP number, and the company expects to comply with the minimum price rule by mid-August.
Lexaria Bioscience CorpReverse stock split to regain Nasdaq compliance; no fundamental change in business value.